Mary Schramke was named acting chief executive officer for Lynx Therapeutics effective Dec. 15, the company said this week. She succeeds Kevin Corcoran who resigned as president, CEO, and director to pursue another business opportunity, the company said. Schramke previously was vice president of business development for Lynx, where she has worked since 2003.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.